Peptidream Inc.

The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2

Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more

Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more

Largest upfront M&A payment for a preclinical biotech in three years 

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential

Deep antibody expertise is a platform for leaps in new assets and technologies as Asia biotechs become increasingly competitive

Plus: Roche gets into radiopharma via PeptiDream deal and updates from Menarini, Merck KGaA, Tolremo, Merck & Co., ARS, Genevoyager

As a pair of biotechs raise a combined $540M in NASDAQ offerings, how have other listings in the sector fared in the aftermarket this year?

Plus: Akeso’s bispecific gets priority review in China, and updates on Merck-Eisai, Sandoz’s Tysabri biosimilar and the IRA

Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas